# CF Reference List

***(compiled between June 2024 –September 2024)***

## Adults & Adolescents

**Amar S., Badeghiesh A., Baghlaf H., Dahan MH.**
Obstetric and neonatal outcomes among pregnant patients with cystic fibrosis.
*Journal of Obstetrics & Gynecology and Reproductive Biology 2024; 300:219-223*

**Cohen-Cymberknoh M., Ariel Dabby M., Gindi Reiss B., Melo Tanner J., Pérez G., Lechtzin N., Polverino E., Perez Miranda J., Gramegna A., Aliberti S., Levine H., Mussaffi H., Blau H., Prais D., Mei-Zahav M., Shteinberg M., Livnat G., Gur M.,et al**
Maternal and fetal outcomes in multiparous women with Cystic Fibrosis
*Respiratory Medicine 2024; 228: e107654*

## Animal Model

**Dastoor P., Muiler C., Garrison A., Egan M., Carlos Dos Reis D., Santos A., Ameen NA.**
Localization and function of humanized F508del-CFTR in mouse intestine following activation of serum glucocorticoid kinase 1 and Trikafta.
*European Journal of Pharmacology 2024; 978: e978:176771*

### Antimicrobials

**Breen SKJ., Harper M., López-Causapé C., Rogers KE., Tait JR., Smallman TR., Lang Y., Lee WL., Zhou J., Zhang Y., Bulitta JB., Nation RL., Oliver A., Boyce JD., Landersdorfer CB.**
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm modelevaluated by mechanism-based modelling and whole genome sequencing.
*International Journal of Antimicrobial Agents 2024; 63(6): e107161*

**Fowler VG Jr., Das AF., Lipka-Diamond J., Ambler JE., Schuch R., Pomerantz R., Cassino C., Jáuregui-Peredo L., Moran GJ., Rupp ME., Lachiewicz AM., Kuti JL., Wise RA., Kaye KS., Zervos MJ., Nichols WG.**
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).
*Clinical Infectious Diseases. 2024; 78: 1473-1481.*

**Jjingo CJ., Bala S., Waack U., Needles M., Bensman TJ., McMaster O., Smith T., Blakely B., Chan IZ., Puthawala K., Dixon C., Kim Y., Lim R., Colangelo P., St Clair C., Nambiar S., Moss RB., Botgros R., Bazaz R., Denning DW., Marr KA., et al**
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.
*Clinical Infectious Diseases. 2024; 78: 1564-1570*

**Li D., Donnelley M., Parsons D., Habgood MD., Schneider-Futschik EK.**
Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy.
*British Journal of Pharmacology 2024; 181: :2413-2428.*

**Mudgil U., Khullar L., Chadha J., Prerna., Harjai K.**
Beyond antibiotics: Emerging antivirulence strategies to combat Pseudomonas aeruginosa in cystic fibrosis.
*Microbial Pathogenesis 2024; 193: e106730.*

**Sherwood SJ., Tak C., Bhakta ZN., Packer K., Jacobs H., Liou TG., Young DC.**
A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic
fibrosis.
*Pediatric Pulmonology 2024; 59: 1740-1746*

## Cardiology

**Amoakon JP., Mylavarapu G., Amin RS., Naren AP.**
Pulmonary Vascular Dysfunctions in Cystic Fibrosis.
*Physiology 2024; 1;39(4):*

## Cell Biology

**Skinner WH., Robinson N., Hardisty GR., Gray RD., Campbell CJ.**
SERS Microsensors for the Study of pH Regulation in Cystic Fibrosis Patient-Derived Airway Cultures.
*ACS Sensors 2024; 9(5): :2550-2557*

## CFTR

**Akram A., Sakhawat A., Ghani MU., Khan MU., Rehman R., Ali Q., Jin-Liang P., Ali D.**
Silibinins and curcumin as promising ligands against mutant cystic fibrosis transmembrane regulator protein.
*AMB Express 2024; 14(1): e84*

**Coatti GC., Vaghela N., Gillurkar P., Leir SH., Harris A.**
A promoter-dependent upstream activator augments CFTR expression in diverse epithelial cell types.
*Biochimica et Biophysica Acta - Gene Regulatory Mechanisms. 2024; 1867(2): e195031.*

**Crunkhorn S.**
Discovering CFTR modulators.
*Nature Reviews Drug Discovery. 2024; 23(8): 581*

**Gao X., Yeh HI., Yang Z., Fan C., Jiang F., Howard RJ., Lindahl E., Kappes JC., Hwang TC.**
Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore.
*Nature Communications 2024; 15(1): e6668*

**Landess L., Prieur MG., Brown AR., Dellon EP.**
Exploring perceptions of and decision-making about CFTR modulators.
*Pediatric Pulmonology 2024; 59: 1614-1621*

**Loske J., Völler M., Lukassen S., Stahl M., Thürmann L., Seegebarth A., Röhmel J., Wisniewski S., Messingschlager M., Lorenz S., Klages S., Eils R., Lehmann I., Mall MA., Graeber SY., Trump S.**
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis. (Comment in Am J Respir Crit Care Med. 2024 Jun 1;209(11):1292-1293.)
*American Journal of Respiratory and Critical Care Medicine 2024; 209: 1338-1350.*

**Luo S., Rollins S., Schmitz-Abe K., Tam A., Li Q., Shi J., Lin J., Wang R., Agrawal PB.**
The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.
*Clinica Chimica Acta. 2024; 561: e119765.*

**Meng X., Ford RC.**
Investigation of F508del CFTR unfolding and a search for stabilizing small molecules
*Archives of Biochemistry and Biophysics. 2024; 758: e110050*

**No authors listed**
Erratum: Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
*American Journal of Respiratory and Critical Care Medicine 2024; 210(2): e249.*

**Reix P., Chassagnon G..**
The younger, the better: lessons learned from real-world studies on CFTR modulators in young children.
*European Respiratory Journal. 2024; 64(3): e2401178*

**Tanjala AC., Jiang JX., Eckford PDW., Ramjeesingh M., Li C., Huan LJ., Langeveld G., Townsend C., Paone DV., Busch-Petersen J., Pekhletski R., Tang L., Raju V., Rowe SM., Bear CE.**
Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells.
*Respiratory Research 2024; 25(1): e269*

**van der Sluijs P., Hoelen H., Schmidt A., Braakman I.**
The Folding Pathway of ABC Transporter CFTR: Effective and Robust.
*Journal of Molecular Biology. 2024; 436(14): e168591*

**Varkki SD., Aaron R., Chapla A., Danda S., Medhi P., Jansi Rani N., Paul GR.**
CFTR mutations and phenotypic correlations in people with cystic fibrosis: a retrospective study from a single centre in south India.
*Lancet Regional Health - Southeast Asia 2024; 27: e100434.*

**Wu M., Davis JD., Zhao C., Daley T., Oliver KE.**
Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment.
*Journal of Clinical and Translational Endocrinology 2024; 36: e100344*

## Clinical

**National Health and Medical Research Council Australia**
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomisedcontrolled phase 4 trial.
*Lancet Respiratory Medicine 2024; 12: 703-713*

**Bush A.**
Learning from cystic fibrosis: How can we start to personalise treatment of Children's Interstitial Lung Disease (chILD)?
*Paediatric Respiratory Reviews 2024; 50: 46-53*

**Carroll BJ., Ostrenga JS., Fink AK., Antos NJ., Cromwell EA., Ren CL.**
Clinical outcomes at 9-10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome.
*Pediatric Pulmonology. 2024; 59: 1606-1613*

**Cuneo A., Smith-Thomas T., Marsac M.**
Opportunities for trauma-informed medical care in cystic fibrosis
*Pediatric Pulmonology 2024; 56: 1814-1816*

**Fischer DL., Vendrusculo FM., de Oliveira JR., Donadio MVF.**
Association of Neutrophil-Lymphocyte Ratio with Clinical Outcomes in Patients with Cystic Fibrosis.
*Indian Journal of Pediatrics 2024; 91: 982*

**Guo J., King I., Hill A.**
International disparities in diagnosis and treatment access for cystic fibrosis.
*Pediatric Pulmonology 2024; 59: 1622-1630*

**Mattison G., Canfell OJ., Smith D., Forrester D., Reid D., Töyräs J., Dobbins C.**
An excellent servant but a terrible master": Understanding the value of wearables for self-management in people with cystic fibrosis and their healthcare providers - A qualitative study.
*International Journal of Medical Informatics 2024; 189: e105532*

**Oppelaar MC., Emond Y., Bannier MAGE., Reijers MHE., van der Vaart H., van der Meer R., Altenburg J., Conemans L., Rottier BL., Nuijsink M., van den Wijngaart LS., Merkus PJFM., Heinen M., Roukema J.**
Potential, Pitfalls, and Future Directions for Remote Monitoring of Chronic Respiratory Diseases: Multicenter Mixed Methods Study in Routine Cystic Fibrosis Care.
*Journal of Medical Internet Research 2024; 26: e54942*

**Sathe M., Stein A**
Remaining barriers to normalcy in cystic fibrosis: Considerations in GI, liver, and nutrition
*Pediatric Pulmonology 2024; S1: S5*

**Smith AD., Schwartzman G., Lyons CE., Flowers H., Albon D., Greer K., Lonabaugh K., Zlotoff BJ**
Cutaneous manifestations of cystic fibrosis.
*Journal of the American Academy of Dermatology 2024; 91: 490-498*

**Sun BZ., Sawicki GS.**
Advances in Care and Outcomes for Children with Cystic Fibrosis.
*Clinics in Chest Medicine 2024; 45: 625-637*

**Tural DA., Emiralioglu N., Akin S., Alboga D., Ozsezen B., Buyuksahin HN., Guzelkas I., Kasikci M., Sunman B., Gungor I., Yalcin E., Dogru D., Kiper N., Demirel AH., Ozcelik U.**
Correction to: Galectin-3 levels in children with cystic fibrosis.
*European Journal of Pediatrics 2024; 183: 3633-3634*

## Diabetes

**Alkhateeb AA., Mancl LA., Ramos KJ., Rothen ML., Kotsakis GA., Trence DL., Chi DL.**
The association between cystic fibrosis-related diabetes and periodontitis in adults: A pilot cross-sectional study.
*PLoS One. 2024; 19(6): e0305975*

**Chokkalla AK., Tuley P., Kurtca M., Ona H., Ruiz FE., Devaraj S.**
Cystic fibrosis-related diabetes screening at a large pediatric center.
*Laboratory Medicine 2024; 55: 580-584*

**Saegebrecht LS., Röhlig M., Schaub F., Ballmann M., Stachs O., Fischer DC**
Glycemic Variability and the Thickness of Retinal Layers in Cystic Fibrosis Patients with and without Cystic Fibrosis Related Diabetes.
*Current Eye Research 2024; 49: 759-767.*

## Endocrinology

**Milano RV., Morneault-Gill K., Kamal HY., Barkin JA., Chadwick CB.**
Pancreatitis in cystic fibrosis: Presentation, medical and surgical management, and the impact of modulator therapies.
*Pediatric Pulmonology 2024; S1: :S53-S60*

**Ramsey ML., Galante GJ.**
Pancreas and pancreatitis: Exocrine pancreatic insufficiency.
*Pediatric Pulmonology 2024; S1: S44-S52*

## Epidemiology

**Rafique H., Safdar A., Ghani MU., Akbar A., Awan FI., Naeem Z., Amar A., Awan MF., Wajahat Ullah S., Shaikh RS.**
Exploring the diversity of CFTR gene mutations in cystic fibrosis individuals of South Asia.
*Journal of Asthma. 2024; 61: 511-519*

## Gastroenterology

**Bertolini A., Nguyen M., Zehra SA., Taleb SA., Bauer-Pisani T., Palm N., Strazzabosco M., Fiorotto R..**
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.
*Journal of Hepatology 2024; 81: :429-440.*

**Lee T., Nissenbaum C.**
Improving gastrointestinal health in children and young people with cystic fibrosis.
*Archives of Disease in Childhood. 2024; 109: 525-526*

**Maisonneuve P.**
Characteristics and Outcomes of Patients with Cystic Fibrosis and Pancreatic Cancer: A Large Database Analysis.
*Journal of Gastrointestinal Cancer. 2024; 55(3): 1467*
**Raza Z., Islam BN., Hachem CY., Cummings LC.**
Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre- and posttransplant.
*Pediatric Pulmonology. 2024; S1: S91-S97*

**Roca M., Masip E., Colombo C., Boon M., Hulst JM., Garriga M., de Koning BAE., Bulfamante A., de Boeck K., Ribes-Koninckx C., Calvo-Lerma J.**
Long-term evaluation of faecal calprotectin levels in a European cohort of children with cystic fibrosis.
*Archives of Disease in Childhood 2024; 109: 552-556.*

**Vélez C., Neuringer I., Schwarzenberg S.**
The foregut in cystic fibrosis.
*Pediatric Pulmonology 2024; S1: :S61-S69*

**Wells H., Bough G., Stedman F., Ekerin AR., Hall NJ**
Investigations, management and outcome of neonates presenting with distal intestinal obstruction: challenging the need for contrast enemas
*Pediatric Surgery International. 2024; 40(1): e154*

## Gene Therapy

**Bulcaen M., Carlon MS.**
Gene editing flows to the lungs. (Comment on Science. 2024 Jun 14;384(6701):1196-1202)
*Science. 2024; 384: 1175-1176*

**Porter JJ., Lueck JD,.**
A cystic fibrosis gene editing approach that is on target.
*Molecular Therapy - Nucleic Acids. 2024; 35(2): e102197.*

## General Review

**Mall MA., Burgel PR., Castellani C., Davies JC., Salathe M., Taylor-Cousar JL.**
Cystic fibrosis.
*Nature Reviews Disease Primers 2024; 10(1): e53*

**Savant A., Lyman B., Bojanowski C., Upadia J.**
Cystic Fibrosis.
*in GeneReviews 2024; : 1993-2024.*

## Genetics

**Guo R., Zou Y., Guo Y., Gao W.**
Compound heterozygous CFTR variants (Q1352H and 5T; TG13) in a Chinese patient with cystic fibrosis.
*Diagnostic Pathology. 2024; 19(1): e107*

**Kumar M., Aaron R., Varkki SD., Danda S., Ranganathan S., Paul GR.**
A rare variant c.1802T>C (p. Ile601Thr) associated with severe phenotype among people with cystic fibrosis from south India, and potential genetic admixture in Réunion, France
*Pediatric Pulmonology. 2024; 59: 1820-1825*

## Growth & Development

**Gabel ME., Gaudio RE., Shaikhkhalil AK.**
Improving growth in infants with CF.
*Pediatric Pulmonology. 2024; S1: :S17-S26*

**Stewart KL., Szczesniak R., Liou TG.**
Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
*Pediatric Pulmonology 2024; 59: 1724-1730*

## Immunology & Inflammation

**Bardin E., Dietrich C., Attailia M., Ferroni A., Jamet A., Lezmi G., Sermet-Gaudelus I., Leite-de-Moraes M.**
Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.
*American Journal of Respiratory and Critical Care Medicine 2024; 210: :243-245*

**Capone M., Vanni A., Salvati L., Lamacchia G., Mazzoni A., Maggi L., Cosmi L., Liotta F., Romagnani P., Cirillo L., Buti E., Terlizzi V., Azzari C., Citera F., Barbati F., Rossolini GM., Bresci S., Borchi B., Cavallo A., Mencarini J.,et al**
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.
*Immunology Letters 2024; 268: e106886.*

**Fuchs T., Zlamy M., Zöggeler T., Appelt D., Niedermayr K., Siedl A., Gasser V., Eder J., Ellemunter H.**
Detection of cytokines in nasal lavage samples of patients with cystic fibrosis: comparison of two different cytokine detection assays.
*BMC Pulmonary Medicine 2024; 24(1): e286*

**Venegas Garrido C., Mukherjee M., Svenningsen S., Nair P.**
Eosinophil-mucus interplay in severe asthma: Implications for treatment with biologicals.
*Allergology International 2024; 73: 351-361*

**Yonker LMv, Kinane TB**
Depths of Dysfunctional Epithelial and Immune Crosstalk in Cystic Fibrosis Revealed. - (Comment on Am J Respir Crit Care Med. 2024 Jun
1;209(11):1338-1350)
*American Journal of Respiratory and Critical Care Medicine. 2024; 209: 1292-1293.*

## Liver Disease

**Declercq M,, Treps L., Geldhof V., Conchinha NV., de Rooij LPMH., Subramanian A., Feyeux M., Cotinat M., Boeckx B., Vinckier S., Dupont L., Vermeulen F., Boon M., Proesmans M., Libbrecht L,, Pirenne J., Monbaliu D., Jochmans I., Dewerchin M., et al**
Single-cell RNA sequencing of cystic fibrosis liver disease explants reveals endothelial complement activation.
*Liver International 2024; 44: 2382-2395*

**Eldredge JA., Oliver MR., Ooi CY.**
Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
*Paediatric Respiratory Reviews 2024; : 54-61*

**Kasper VL., Assis DN.**
Pathophysiology of Cystic Fibrosis Liver Disease.
*Pediatric Pulmonology 2024; : S98-S106*

**Palle SK., Leung DH.**
Advanced cystic fibrosis liver disease: Endovascular, endoscopic, radiologic, and surgical considerations.
*Pediatric Pulmonology 2024; S1: S115-S122*

**Sankararaman S., Freeman AJ.**
Early detection of hepatobiliary involvement in cystic fibrosis: Biomarkers, radiologic methods, and genetic influences.
*Pediatric Pulmonology. 2024; S1: S107-S114*

## Microbiology

**Adariani AR., Sokhanvari S., Nikbin VS., Hosseinzadeh M., Khoram Z., Solgi H.**
First case of New Delhi metallo beta-lactamase-1 (NDM-1)-producing Burkholderia cepacia complex in Iran.
*Heliyon 2024; 10(10):: e30895*

**Almeida MM., Bastos LR., Firmida MC., Albano RM., Marques EA., Leão RS.**
Genomic Comparative of Pseudomonas aeruginosa Small Colony Variant, Mucoid and Non-mucoid Phenotypes Obtained from a Patient with Cystic Fibrosis During Respiratory Exacerbations.
*Current Microbiology 2024; 81(9): e274*

**Ciszek-Lenda M., Nowak B., Majka G., Suski M., Walczewska M., Fedor A., Goli?ska E., Górska S., Gamian A., Olszanecki R., Strus M., Marcinkiewicz J.**
Saccharomyces cerevisiae beta-glucan improves the response of trained macrophages to severe P. aeruginosa infections.
*Inflammation Research 2024; 73: 1283-1297*

**Crabbé A**
Intracellular Pseudomonas aeruginosa: An Overlooked Reservoir in the Lungs of People with Cystic Fibrosis? (Comment on Am J Respir Crit Care Med.
2024: 209:1421-1423)
*American Journal of Respiratory and Critical Care Medicine 2024; 209: 1421-1423*

**Crisan CV., Pettis ML., Goldberg JB.**
Antibacterial potential of Stenotrophomonas maltophilia complex cystic fibrosis isolates.
*mSphere 2024; 9(7): e0033524*

**Duncan RP., Moustafa DA., Lewin GR., Diggle FL., Bomberger JM,, Whiteley M., Goldberg JB.**
Improvement of a mouse infection model to capture Pseudomonas aeruginosa chronic physiology in cystic fibrosis.
*Proceedings of the National Academy of Sciences 2024; 121(33): e2406234121*

**George M., Narayanan S., Tejada-Arranz A., Plack A., Basler M.**
Initiation of H1-T6SS dueling between Pseudomonas aeruginosa.
*mBio 2024; 15(8): e0035524*

**Green N., Chan C., Ooi CY.**
The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis.
*Pediatric Pulmonology. 2024; S1: :S70-S80*

**Hofstaedter CE., O'Keefe IP., Met CM., Wu L., Vanderwoude J., Shin S., Diggle SP., Riquelme SA., Rasko DA., Doi Y., Harro JM., Kopp BT., Ernst RK.**
Pseudomonas aeruginosa Lipid A Structural Variants Induce Altered Immune Responses.
*American Journal of Respiratory Cell and Molecular Biology 2024; 71: 207-218*

**Kruk ME., Mehta S., Murray K., Higgins L., Do K., Johnson JE., Wagner R., Wendt CH., O'Connor JB., Harris JK., Laguna TA., Jagtap PD., Griffin TJ.**
An integrated metaproteomics workflow for studying host-microbe dynamics in bronchoalveolar lavage samples applied to cystic fibrosis disease. *mSystems 2024; 9(7): :e0092923*

**Lagune M., Kremer L., Herrmann JL..**
Mycobacterium abscessus, a complex of three fast-growing subspecies sharing virulence traits with slow-growing mycobacteria.
*Clinical Microbiology and Infection 2024; 30: 726-731*

**Malet K., Faure E., Adam D., Donner J., Liu L., Pilon SJ., Fraser R., Jorth P., Newman DK., Brochiero E', Rousseau S., Nguyen D..** Intracellular Pseudomonas aeruginosa within the Airway Epithelium of Cystic Fibrosis Lung Tissues. (Comment on Am J Respir Crit Care Med. 2024: 209:1421-1423)
*American Journal of Respiratory and Critical Care Medicine 2024; 209: 1453-1462*

**Mangiaterra G., Schiavoni V., Cedraro N., Citterio B., Vignaroli C., Gesuita R., Fabrizzi B., Biavasco F., Cirilli N.**
Clinical relevance of Pseudomonas aeruginosa viable but non-culturable forms in cystic fibrosis.
*European Journal of Clinical Microbiology & Infectious Diseases 2024; 43: 1865-1867.*

**Maruri-Aransolo A., López-Causapé C., Hernández-García M., García-Castillo M., Caballero-Pérez JD., Oliver A., Cantón R..**
In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.
*Journal of Antimicrobial Chemotherapy 2024; 79: 1432-1440*

**Millar BC., Bell J., Rendall JC., Moore JE.**
Carriage of Neisseria meningitidis (meningococci) in the sputum of people with cystic fibrosis (CF): occupational health risks and mitigating interventions for physiotherapists.
*Physiotherapy. 2024; 124: 101-105*

**Mossop M., Ish-Horowicz J., Hughes D., Dobra R., Cunanan AG., Rosenthal M., Carr SB., Ramadan N., Nolan LM., Davies JC.**
Chronicity Counts: The Impact of Pseudomonas aeruginosa, Staphylococcus aureus, and Coinfection in Cystic Fibrosis.
*American Journal of Respiratory and Critical Care Medicine 2024; 210: 240-242*

**Palucci I., Delogu G.**
Alternative therapies against Mycobacterium abscessus infections.
*Clinical Microbiology and Infection 2024; 30: :732-737*

**Sheykhsaran E., Abbasi A., Memar MY., Ghotaslou R., Baghi HB., Mazraeh FN., Laghousi D., Sadeghi J.**
The role of Staphylococcus aureus in cystic fibrosis pathogenesis and clinico-microbiological interactions.
*Diagnostic Microbiology and Infectious Disease 2024; 109(3): e116294.*

**Stoodley P., Toelke N., Schwermer C., de Beer D.**
Bioenergetics of simultaneous oxygen and nitrate respiration and nitric oxide production in a Pseudomonas aeruginosa agar colony biofilm.
*Biofilm. 2024; 17: e100181*

**Tony-Odigie A., Dalpke AH., Boutin S., Yi B.**
Airway commensal bacteria in cystic fibrosis inhibit the growth of P. aeruginosa via a released metabolite.
*Microbiological Research. 2024; 283: e127680*

**Weimann A., Dinan AM., Ruis C., Bernut A., Pont S., Brown K., Ryan J., Santos L., Ellison L., Ukor E., Pandurangan AP., Krokowski S., Blundell TL., Welch M., Blane B., Judge K., Bousfield R., Brown N., Bryant JM., Kukavica-Ibrulj I, Rampioni G.,et al**
Evolution and host-specific adaptation of Pseudomonas aeruginosa.
*Science. 2024; 385(6704): :eadi0908*

**Yap ZL., Rahman ASMZ., Hogan AM., Levin DB., Cardona ST..**
A CRISPR-Cas-associated transposon system for genome editing in Burkholderia cepacia complex species.
*Applied and Environmental Microbiology 2024; 90(7): e0069924*

## Nutrition

**Bass R., Alvarez JA.**
Nutritional status in the era of highly effective CFTR modulators.
*Pediatric Pulmonology 2024; S1: S6-S16*

**Jobanputra AM., Kesavarapu K., Naik S., Ramagopal M., Scharf MT., Jagpal S.**
Overnutrition in persons with cystic fibrosis on modulator therapy and the relationship to obstructive sleep apnea.
*Pediatric Pulmonology. 2024; S1: S27-S35*

**Lyons ER., Muther E., Sabharwal S.**
Nutrition and behavioral health in cystic fibrosis: Eating and body image.
*Pediatric Pulmonology 2024; S1: S36-S43*

**Shrivastava S., Shaw K., Lee M., Reitich P., Hunter S., Klosterman M., Sathe M.**
Association of in-line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis.
*Nutrition in Clinical Practice. 2024; 39: :903-910*

**Smith C., Lowdon J., Noordhoek J., Wilschanski M.**
Evolution of nutritional management in children with cystic fibrosis - a narrative review
*Journal of Human Nutrition and Dietetics. 2024; 37: :804-814*

**Suppakitjanusant P., Wang Y., Sivapiromrat AK., Hu C., Binongo J., Hunt WR., Weinstein S., Jathal I., Alvarez JA., Chassaing B., Ziegler TR., Gewirtz AT., Tangpricha V.**
Impact of high-dose cholecalciferol (vitamin D3) and inulin prebiotic on intestinal and airway microbiota in adults with cystic fibrosis: A 2 × 2 randomized,
placebo-controlled, double-blind pilot study.
*Journal of Clinical and Translational Endocrinology. 2024; 37: e100362*

## Physiotherapy

**Morrison L., McCrea G., Palmer S.**
Online activity - A beaming good initiative! Delivering alternative exercise opportunities for people with cystic fibrosis.
*Physiotherapy Theory and Practice. 2024; 40: 1609-1615*

**Sinderholm Sposato N., Bjerså K., Gilljam M., Lannefors L., Fagevik Olsén M.**
Effectiveness of manual therapy interventions in cystic fibrosis care: a pilot study.
*Journal of Bodywork and Movement Therapies 2024; 39: 323-329*

**Vidal T., Reychler G., Sorlat-Maire C., Perceval M., Nove-Josserand R', Durieu I., Reynaud Q**
Adherence to chest physiotherapy in adults with cystic fibrosis
*Revue des Maladies Respiratoires. 2024; 41: 455-462*

## Psychosocial

**Blais A., Katz SL., Klaassen RJ., Lougheed J., Reisman JJ., Pohl D., Lawrence S., Lai L., Lee S., Gardin L., Wong D., Sell E., Longmuir P..** Understanding the physical literacy development of 8- to 12-year-old children living with chronic medical conditions: A comprehensive, mixed methods inquiry.
*Child: Care, Health and Development. 2024; 50(5): e13316.*

**Duck SA., Jansen E., Papantoni A., Sheltry A., Koinis-Mitchell D., D'Sa V., Deoni S., Moran TH., Findling RL., Mogayzel PJ Jr., Carnell S.**
Parental perceptions of body weight and appetite in infants and toddlers with cystic fibrosis.
*Appetite 2024; 198: e:107357*

**Duff AJA., Lee TWR.**
Reply to Piehler et al.: Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
*American Journal of Respiratory and Critical Care Medicine. 2024; 210: 367*

**Gamel B., Albon D., Bandla S., Davison DW., Flath J., Sabadosa KA., Seid M., Silva L., Ong T.; Cystic Fibrosis Learning Network Group.**
Interventions to improve system-level coproduction in the Cystic Fibrosis Learning Network.
*BMJ Open Quality, 2024; 13(30: e002860*

**Ladune R., Hayotte M., Vuillemin A', d'Arripe-Longueville F.**
Development of a Web App to Enhance Physical Activity in People With Cystic Fibrosis: Co-Design and Acceptability Evaluation by Patients and Health Professionals.
*JMIR Formative Research. 2024; 8: e54322*

**Liu CM., Han EJ., Fischer JL., Mace JC., Mattos JL., Markarian K., Alt JA., Bodner TE., Chowdhury NI., Eshaghian PH., Getz AE., Hwang PH., Khanwalkar A., Kimple AJ., Lee JT., Li DA., Norris M., Nayak JV., Owens C., Patel ZM., Poch K., et al**
Patient perspectives on chronic rhinosinusitis in cystic fibrosis: Symptom prioritization in the era of highly effective modulator therapy.
*International Forum of Allergy & Rhinology. 2024; 14: 1282-1293*

**Piehler L., Thalemann R., Lehmann C., Stahl M., Mall MA., Graeber SY.**
Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
*American Journal of Respiratory and Critical Care Medicine 2024; 210: 365-367*

**Sermet-Gaudelus I., Benaboud S., Bui S., Bihouée T., Gautier S.; MODUL-CF study group.**
Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis.
*Lancet. 2024; 404: 117-120*

**Shadi D., Jabraeili M., Hassankhani H., Alhani F., Bostanabad MA.**
Development and validation of a supportive programme for family caregivers of children suffering from cystic fibrosis: protocol for a sequential exploratory mixed-methods study.
*BMJ Open. 2024; 14(6): e081560*

**Silvestri L., Issanchou D., Schuft L., Ferez S.**
How workplaces produce or reduce disability along the career paths of young people with cystic fibrosis
*Health 2024; 28: 507-525*

## Pulmonology

**Bech M., Skov M., Andersen ISB., von Buchwald C., Aanæs K.**
The criteria for chronic rhinosinusitis in children with cystic fibrosis are rarely fulfilled after initiation of CFTR modulator treatment.
*APMIS 2024; 132: 625-631*

**Beswick DM., Liu CM., Overdevest JB., Zemke A., Khatiwada A., Gudis DA., Miller JE., Kimple A., Tervo JP., DiMango E., Goralski JL., Keating C., Senior B., Stapleton AL., Eshaghian PH., Mace JC., Markarian K., Alt JA., Bodner TE., et al**
Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
*Laryngoscope. 2024; 134: 3965-3973*

**Harris ES., McIntire HJ., Mazur M., Schulz-Hildebrandt H., Leung HM., Tearney GJ., Krick S., Rowe SM., Barnes JW.**
Reduced sialylation of airway mucin impairs mucus transport by altering the biophysical properties of mucin.
*Scientific Reports 2024; 14(1): e16568.*

**Mazio C., Scognamiglio LS., Casale C., Panzetta V., Urciuolo F., Galietta LJV., Imparato G., Netti PA.**
A functional 3D full-thickness model for comprehending the interaction between airway epithelium and connective tissue in cystic fibrosis.
*Biomaterials 2024; 308: e122546*

**Naseem R., Howe N., Williams CJ., Pretorius S., Green K**
What diagnostic tests are available for respiratory infections or pulmonary exacerbations in cystic fibrosis: A scoping literature review.
*Respiratory Investigation 2024; 62: 817-831*

**Sousa AM., Pereira MO.**
Challenges with drug efficacy prediction of in vitro models of biofilms infecting cystic fibrosis airway.
*Expert Opinion on Drug Discovery. 2024; 19: 635-638.*

## Radiology

**Bugenhagen SM., Grant JCE., Rosenbluth DB., Bhalla S.**
Update on the Role of Chest Imaging in Cystic Fibrosis.
*Radiographics 2024; 44(9): e240008.*

**David M., Benlala I., Bui S., Benkert T., Berger P., Laurent F., Macey J., Dournes G..**
Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times.
*Journal of Magnetic Resonance Imaging 2024; 60: 116-124.*

**Mustafina M., Silantyev A., Krasovskiy S., Chernyak A., Naumenko Z., Suvorov A., Gognieva D., Abdullaev M., Bektimirova A., Bykova A.,Dergacheva V., Betelin V., Kopylov P.**
Exhaled breath analysis in adult patients with cystic fibrosis by real-time proton mass spectrometry.
*Clinica Chimica Acta. 2024; 560: e119733*

**Navas-Moreno V., Sebastian-Valles F., Rodríguez-Laval V., Knott-Torcal C., Marazuela M., de la Blanca NS., Arranz Martín JA., Girón RM.,**
**Sampedro-Núñez MA.**
Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study.
*Nutrition 2024; 123: e112425.*

## Therapy

**Arenhoevel J., Kuppe A., Addante A., Wei LF., Boback N., Butnarasu C., Zhong Y., Wong C., Graeber SY., Duerr J., Gradzielski M., Lauster D., Mall MA., Haag R.**
Thiolated polyglycerol sulfate as potential mucolytic for muco-obstructive lung diseases.
*Biomaterials Science 2024; 12(17):: 4376-4385.*

**Chun SW., Somers ME., Burgener EB.**
Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
*Current Opinion in Pediatrics 2024; 36: 290-295*

**Hansen CME., Breukelman AJ., van den Bemt PMLA., Zwitserloot AM., van Dijk L., van Boven JFM.**
Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review.
*European Respiratory Review. 2024; 33(173): e240060*

**Hong E., Zampoli M., Beringer PM.**
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
*Clinical Pharmacology & Therapeutics 2024; 115: 1204-1207.*

**Jarosz-Griffiths HH., Gillgrass L., Caley LR., Spoletini G., Clifton IJ., Etherington C., Savic S., McDermott MF., Peckham D.**
Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del.
*PLoS One. 2024; 19: :e0304555*

**Mazio C., Scognamiglio LS., Casale C., Panzetta V., Urciuolo F., Galietta LJV., Imparato G., Netti PA. Cohen A., Mass A., Reiter J., Zangen DH., Cohen-Cymberknoh M.**
Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis
*Respiratory Medicine. 2024; 228: e107664.*

**McKinzie CJ., Kam CW., Jones MC., Gifford LB., Loughlin CE., Noah TL., Shenoy VK., Dellon EP.**
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.
*Pediatric Pulmonology 2024; 59: 1795-1797*

**Pudukodu H., Powell MZ., Ceppe A., Donaldson SH., Goralski JL., Sowa NA.**
Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis.
*Clinical Respiratory Journal . 2024; 18(9): :e70007*

**Sandler RD., Lai L., Dawson S., Cameron S., Lynam A., Sperrin M., Hoo ZH., Wildman MJ.**
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system.
*Expert Review of Pharmacoeconomics & Outcomes Research 2024; 24: 759-771*

**Stahl M., Dohna M., Graeber SY., Sommerburg O., Renz DM., Pallenberg ST., Voskrebenzev A., Schütz K., Hansen G., Doellinger F., Steinke E., Thee S, Röhmel J., Barth S., Rückes-Nilges C., Berges J., Hämmerling S., Wielpütz MO., Naehrlich L., et al**
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
*European Respiratory Journal 2024; 64(3): e:2400004*

**Stastna N., Hrabovska L., Homolka P., Homola L., Svoboda M., Brat K., Fila L.**
The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study.
*BMC Pulmonary Medicine. 2024; 24(1): e260.*

**Turuvekere Vittala Murthy N., Vlasova K., Renner J., Jozic A., Sahay G.**
A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines.
*Advanced Drug Delivery Reviews 2024; 209: e115305*

**Woynarowski M., Sapiejka E., Jó?wiak M., Milczewska J., Zybert K., Krusi?ski A., Siwiec J., Wierzbicka-Ruciska A.** Macroenzymes as a reason for aminotransferases flare in cystic fibrosis patients on CFTR modulators therapy - Report of three cases. *Heliyon 2024; 10(10): :e31189.*